Search | Clinical Trials Finder

Conditions: Cystic Fibrosis
Interventions: AZLI 75 mg three times a day (TID), Placebo three times a day (TID); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 40
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more

Conditions: Relapsed / Recurrent Germ Cell Tumors
Interventions: Erlotinib, Sirolimus; Drug
Lead sponsor: Theodore Laetsch; Other
Eligibility: 12 Months to 50 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • Memphis, Tennessee • Dallas, Texas

Conditions: Hyperbilirubinemia, Premature Newborns, Extremely Low Birth Weight
Interventions: phototherapy; Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Up to 24 Hours
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 6
States / cities: Birmingham, Alabama • Palo Alto, California • Cincinnati, Ohio + 3 more

Conditions: Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
Interventions: NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane, NGM120 100mg with Gemcitabine and Abraxane, NGM120 100mg Q3W, Placebo; Biological · Other
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more

Conditions: Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Interventions: BIIB080, BIIB080-matching placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 36
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more

Conditions: Hepatitis, Chronic Active
Interventions: CPG10101, Control; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 13
States / cities: Miami, Florida • Chicago, Illinois • Indianapolis, Indiana + 10 more

Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
Interventions: CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]; Drug
Lead sponsor: Cytovation AS; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more

Conditions: Post Traumatic Stress Disorder
Interventions: Active rTMS, Sham rTMS, Cognitive Processing Therapy; Device · Behavioral
Lead sponsor: The University of Texas at Dallas; Other
Eligibility: 18 Years to 60 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 3
States / cities: Tallahassee, Florida • Addison, Texas • Dallas, Texas

Conditions: Inguinal Hernia, Pain
Interventions: SEMPERFLO Pain Management System, ON-Q PainBuster Post-Op Pain Relief System; Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Boca Raton, Florida • Jacksonville, Florida • St Louis, Missouri + 3 more

Conditions: Chronic Spontaneous Urticaria
Interventions: CDX-0159, Normal Saline; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Birmingham, Alabama • Gilbert, Arizona • Sarasota, Florida + 10 more

Conditions: Preterm Birth
Interventions: Hydroxyprogesterone Caproate Injection (HPC), 250mg/mL, Vehicle; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 41
States / cities: Montgomery, Alabama • Tucson, Arizona • La Mesa, California + 35 more

Conditions: NF1, Congenital Pseudarthrosis of Tibia
Interventions: INFUSE Bone Graft (BMP-2), Control Group; Device · Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 2 Years to 18 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 10 more

Conditions: Advanced Solid Tumor
Interventions: TTX-MC138; Drug
Lead sponsor: TransCode Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Dallas, Texas • Houston, Texas • West Valley City, Utah + 1 more

Conditions: Surgery, Perioperative/Postoperative Complications
Interventions: Not listed
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Thrombocytopenia
Interventions: Avatrombopag; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Timeline: 2018 – 2019
U.S. locations: 41
States / cities: Chandler, Arizona • Lancaster, California • Los Angeles, California + 37 more

Conditions: Coronary Artery Disease, Myocardial Infarction
Interventions: IVL with Shockwave C2+ 2Hz Coronary IVL Catheter; Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 18
States / cities: Huntsville, Alabama • La Jolla, California • Washington D.C., District of Columbia + 15 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Frexalimab, Placebo, Insulin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 14
States / cities: San Francisco, California • Aurora, Colorado • Gainesville, Florida + 11 more

Conditions: Cardiovascular Disease
Interventions: dialysis; Procedure
Lead sponsor: Dallas VA Medical Center; Federal
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Coronary Artery Disease
Interventions: COBRA PzF; Device
Lead sponsor: CeloNova BioSciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 22
States / cities: Bakersfield, California • Miami Beach, Florida • Atlanta, Georgia + 18 more

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 1356, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 13
States / cities: Birmingham, Alabama • Los Angeles, California • National City, California + 9 more

Conditions: Hepatitis C
Interventions: TMC435, PSI-7977 (GS7977), Ribavirin; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 22
States / cities: Hoover, Alabama • Bakersfield, California • La Jolla, California + 19 more

Conditions: Seasonal Allergic Rhinitis
Interventions: levocetirizine dihydrochloride, placebo; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more

Conditions: Phelan-McDermid Syndrome, Autism Spectrum Disorder, Intellectual Disability
Interventions: No Intervention; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 22 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: Stanford, California • Chicago, Illinois • Bethesda, Maryland + 3 more

Conditions: Advanced NET of GI Origin, Advanced NET of Lung Origin, Neuroendocrine Tumors
Interventions: Everolimus, Placebo, Best suportive care (BSC); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 17
States / cities: La Jolla, California • Los Angeles, California • Aurora, Colorado + 11 more

Search by objective public record fields.

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors

Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants?

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD

SEMPERFLO* Pain Management System in Inguinal Hernia Repair

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery

A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)

Study of TTX-MC138 in Subjects With Advanced Solid Tumors

The Perioperative Management of Anti-thrombotic Drug Registry

Avatrombopag for the Treatment of Thrombocytopenia in Adults With Chronic Liver Disease Undergoing a Procedure

Shockwave C2+ 2Hz Coronary IVL Catheter in Calcified Coronary Arteries (Disrupt CAD DUO)

FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)

Decreasing Dialysis Cardiovascular Risk: Daily Versus Longer Treatments

COBRA PZF™ Coronary Stent for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term DAPT

Randomized, Double-blind (db), Placebo-controlled 18 Week Study of Linagliptin (BI 1356) in Type 2 Diabetic Patients With Insufficient Glycaemic Control on a Sulfonylurea Drug

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients

A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis

Mapping the Phenotype in Adults With Phelan-McDermid Syndrome

Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)